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Summary.-Concentrations of circulating immune complexes (CIC) were measured
serially during chemotherapy of 22 patients with gestational trophoblastic tumours
(GTT) and 11 patients with malignant teratoma (MT) by the polyethylene glycol
precipitation and CIq solid-phase assays. Results were correlated with tumour res-
ponse as measured by serum concentrations of human chorionic gonadotrophin
(hCG) and a-foetoprotein (AFP). CIC concentrations correlated with disease status
in the early stages of treatment in 4/22 patients with GTT and 5/11 with MT. CIC
assays were less sensitive than hCG and AFP as a monitor of disease, and also less
specific, in that 8 patients with GTT and 5 with MT developed raised CIC concentra-
tions during chemotherapy in spite of sustained complete remission. Measurements
of CIC concentrations by present methods are neither sufficiently sensitive nor speci-
fic to be of clinical value as a tumour marker in GTT and MT, and this casts doubt
ontheirpotentialvalue in other malignancies. Attention should bedirected to identifi-
cation of the components of CIC, some of which may be more cancer-specific.
RAISED CONCENTRATIONS of circulating
immune complexes (CIC) are found in
several types of cancer of man and experi-
mental animals (for review see Baldwin &
Robins, 1980). There is evidence that in
some cases the antigen component of the
complexes may be a tumour product (for
review see Theofilopoulos & Dixon, 1980;
Nydegger, 1980). Furthermore it has been
suggested that concentrations of CIC
correlate with tumour volume, and this
has been demonstrated in some instances
of viral and chemically induced tumours
of experimental animals (Jennette &
Feldman, 1977; Jennette, 1980). Less
well defined correlations with tumour
volume have been found in patients with
several types of cancer. High values are
common in relapse or before treatment,
particularly with advanced stages of
disease, and there is a tendency for the
results to be normal in remission (for
review see Baldwin & Robins, 1980).
These studies have led to the suggestion
that measuremnnt of CIC concentrations
may provide a tumour-marker system
which will be of value in the management
ofpatientswith cancer (Baldwin & Robins,
1980). In order to be useful, such a tumour
marker must either be more sensitive or
more specific than current methods of
tumour assessment. In malignancies such
as gestational trophoblastic tumours
(GTT) or malignant teratoma (MT), for
which satisfactory biochemical markers
are already available (Javadpour, 1979;
Bagshawe & Searle, 1977), it is clear that
measurement oftumour volume by clinical
examination or conventional radiology
can give a misleading assessment of the
number of viable malignant cells (Bag-
shawe, 1973; Newlands et al., 1980). In
order to assess the value of CICs as a
tumour marker we have therefore com-
pared them with established biochemical
markers the concentrations of which are
related to viable tumour mass, namely
human chorionic gonadotrophin (hCG) inR. H. J. BEGENT ET AL:
GTT and a-foetoprotein (AFP) and hCG
in MT.
MATERIALS AND METHODS
Patients and samples. Serum samples for
measurement of CIC concentrations were
taken serially from 22 patients with GTT
requiring chemotherapy for invasive mole
or choriocarcinoma (age 18-52, median
25 years) and 11 patients with advanced
MT (age 17-41, median 25 years) before and
during chemotherapy. The MT originated in
the testis in 9 patients, the mediastinum in
1 and the ovary in 1. Control sera were ob-
tained from 43 healthy volunteers of both
sexes (age 19-68, median 31 years) and 29
patients with rheumatoid arthritis (whose
sera were kindly donated by Professor R. N.
Maini, the Kennedy Institute, London,
W6). Immediately after separation, serum
was aliquoted and frozen at -20°C, or at
-70°C for storage in excess of 4 weeks.
Patients were all treated with cytotoxic
chemotherapy as described for GTT by Bag-
shawe & Begent (1981) and for MT as des-
cribed by Newlands et al. (1980).
Circulating immune complexes-.Two tests
were used in parallel: the CIq solid-phase
assay (CIqSP) and polyethylene glycol (PEG)
precipitation. The CIqSP was performed as
described by Hardin et al. (1979). The PEG
precipitation assay was modified from the
method of Kazatchkine et al. (1980). One
hundred and fifty pl of4% PEG in barbitone-
buffered saline containing 60 mm EDTA
(pH 7 6) was added to duplicate 150u1l
samples of serum. After 16 h at 4°C, samples
were centrifuged at 1500 g for 20 min at
4°C, washed in 2% PEG and redissolved at
room temperature in 150 pl of barbitone
buffer. The amount of IgG in the redissolved
precipitate was determined by radial immune
diffusion in 0.8%/ agarose (Mercia Brocades
MX agarose for gel electrophoresis) contain-
ing suitable amounts of antisera (Dako anti-
human IgG heavy-chain specific).
Tumour markers.-Human chorionic gona-
dotrophin (normal range < 10 iu/l) was
measured by automated radioimmunoassay
using an antiserum directed against the f
subunit (Kardana & Bagshawe, 1976; Bag-
shawe, 1975). x-Foetoprotein (normal range
<10 jtg/l) was measured using a double-
antibody radioimmunoassay. These assays
were performed twice wveekly during treat-
ment.
Total serum IgG.-This was quantitated by
solid-phase radioimmunoassay (Walker et al.,
1978).
RESULTS
Concentrations of CIC were measured
serially by the PEG precipitation and
CIqSP assays in patients receiving chemo-
therapy for GTT and MT. Results were
correlated with values of the conventional
serum tumour markers, hCG and AFP,
and complete remission (CR) was defined
by normal hCG and AFP concentrations.
The validity of responses and remissions
defined by hCG or AFP values was con-
firmed by clinical examination and con-
ventional radiology, including computeri-
zed tomography where appropriate.
PEG precipitation assay
Results for the normal group are shown
in Fig. 1. Values above 20-6 jig IgG/ml
of serum (mean+ 2 s.d.) were considered
abnormal. 29 patients with rheumatoid
arthritis served as a positive control
group (Fig. 1).
Gestational trophoblastic tumours
CIC concentrations were raised before
treatment in 6/22 patients, this being
significantly more than in the normal
group (P= 0.025 by x2). There was no
correlation with tumour load as measured
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FIG. 1. CIC concentrations measured by PEG
precipitation assay in patients with GTT
and controls.
I
218
IIMMUNE COMPLEXES AS TUMOUR MARKERS
I I I 11
Cytotoxic chemothrp
le .~~~~~~~40
1 ~301 g102 lop 020'
I lo S 10
0
0
0 **
*6'
I.
.,
IO uv ..
',X.4 0
*~~~~~..-O 1 .o|-:f
FIG. 2. Relationship of pre-treatment CIC
concentrations to AFP in MIT (A*) and
to hCG in MT (0) and in GTT (0).
When both markers were present in one
patient with MT (6 cases) only the marker
giving the higher value is shown.
by concentrations of hCG (Fig. 2). Se-
quential studies of the 22 patients (3-35,
median 12, assays per patient) during
treatment (lasting 2-36, median 19, weeks)
identified 3 patterns of behaviour: cor-
relation with hCG, raised CIC concentra-
tions in spite of sustained CR and normal
values throughout treatment. A simplified
representation of the results in the 20
patients who achieved CR is given in
Fig. 1. Analysis of individual patients
included some with raifibd values between
CR and the end of treatment, which
cannot be shown in Fig. 1. This more
detailed analysis gave the following results
for the 3 groups:
1. Correlation with HCG.-In 4/6
patients in whom CIC concentrations
were raised before treatment, values
returned to normal either by CR or the
end of treatment (Fig. 1). In a further
patient there was no response to chemo-
therapy and she is therefore excluded
from Fig. 1. CIC concentrations remained
high. The 6th patient with raised CIC
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FIG. 3. Chart showing conicentrations of
htCG and CIC in a patient during chemo-
therapy foi GTT. CIC concentrations were
raised before treatment, falling to normal
in association with a response to treatment,
shown by a fall in hCG. CIC values later
rose falling to normal after chemotherapy
was stopped. hCG remained undetectable
or at very low levels during this time,
indicating CR.
values before treatment is included in
Group 2.
2. Raised CIC concentrations (in 2 or
more consecutive specimens) in spite of
sustained CR.-7/8 patients in whom
this occurred had normal values before
treatment. The remaining patient had
high values before treatment which be-
came normal when CR was achieved and
later rose once more. The increases occur-
red after 4-19 (median 10) weeks' chemo-
therapy, and did not appear to predict
relapse, since 7/8 patients remain in CR
18-22 months after entry to the study.
The 8th patient did relapse after stopping
chemotherapy, but CIC concentrations
had become consistently normal by this
time.
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FIG. 4. Chart showing concentrations of
AFP and CIC in a patient with MT. CIC
concentrations were normal before treat-
ment, rising during chemotherapy and
returning to normal after finishing treat-
ment. The patient then relapsed with rising
AFP values but not CIC concentrations.
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FIG. 5. CIC concentrations measured by
PEG precipitation in patients with MT.
3. Normal values of CIC throughout
treatment.-8 patients in this group
achieved sustained CR and the 9th died
after 2 weeks without responding to
treatment.
A detailed profile of one representative
patient is shown in Fig. 3.
Malignant teratoma
CIC concentrations were raised before
treatment in 5 of 11 patients, but there
was no correlation with concentrations of
hCG or AFP (Fig. 2). Sequential studies
of all patients (6-31 assays per patient,
median 21) during treatment (lasting
12-48 weeks, median 26) showed similar
patterns of behaviour to GTT and a
simplified representation of the results
in the 10 patients who achieved CR is
given in Fig. 5.
Correlation with disease status
In the 5 patients with raised concen-
trations of CIC before treatment, values
fell to normal at CR, as defined by normal
hCG and AFP levels. One patient later
relapsed with rising hCG and CIC con-
centrations rose at the same time.
Raised CIC concentrations (in 2 or more
consecutive specimens) in spite of sustained
remission
This occurred in 4 patients with normal
values before treatment. In a further
patient they had been raised before treat-
ment then become normal with CR and
FIG. 6.-Chart showing concentrations of
hCG and CIC in a patient with MT.
CIC values returned to normal in associa-
tion with a response to chemotherapy,
but gave a less sensitive indication of
disease status than hCG.
later rose again before treatment was
completed. The rises occurred 1-16 weeks
(median 8) after starting chemotherapy
and did not appear to predict relapse,
since 4 of the patients remain in CR
15-21 months (median 18) after entry to
the study. The 5th relapsed after finishing
chemotherapy, but CIC concentrations
had become consistently normal by then
(Fig. 4).
Normal values of CIC throughout treatment
One of the 2 patients in this group
attained sustained CR and the other a
partial remission.
A detailed example of a further patient
is given in Fig. 6. In order to investi-
gate whether raised values in the PEG
precipitation assay could be explained
by raised total serum IgG concentra-
tions, the results of these two measure-
ments were compared in all patients
before treatment. No statistically signifi-
cant correlation was found by Spearman's
rank-correlation test for the patients
with GTT (rs =0.24) nor for those with
MT (r. = 0.3). Total serum IgG was also
measured serially in 4 patients in whom
raised values were found in the PEG
precipitation assay during the course of
the disease. No correlation was seen be-
tween changes in PEG assay results and
total serum IgG.
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CIqSP assay
Results in patients with GTT and MT
did not differ significantly from those of
the normal group, and there was a good
correlation with results of the PEG
precipitation assay in patients with
rheumatoid arthritis (rs= 0 72, P < 0 001,
by Spearman's rank-correlation test).
DISCUSSION
The results show that measurement of
CIC concentrations in GTT and MT does
not provide a satisfactory tumour-marker
system for clinical use. Even in those
patients in whom falls in CIC concentra-
tion correlated with response to treatment,
the sensitivity was inferior to that of hCG
or AFP, and probably no better than clini-
cal examination orradiological assessment.
The most serious deficiency, however,
is in specificity; there were rises in CIC
concentration during cytotoxic chemo-
therapy in patients with sustained and
well documented CR. In all 4 of the
patients in whom serum samples were
available after treatment, CIC concen-
trations returned to normal, suggesting
that the chemotherapy itself might be
responsible.
The effects of chemotherapy on CIC
formation are likely to be complex. For
example, eradication of tumour leads to
removal of tumour products which might
be antigen components of CIC, thus
accounting for a fall in CIC concentrations
during the early stages of chemotherapy.
Cytotoxic drugs also affect antibody
production, and it has been suggested
that the effect is particularly marked on
T-suppressor-cell function (Diamantstein
et al., 1979; Athanassiades et al., 1978).
Rheumatoid-factor levels have been shown
to rise in patients receiving treatment for
breast and bronchial cancer (Twomey
et al., 1976) and this may reflect a more
generalized disturbance of antibody pro-
duction leading to increased autoantibody
formation and perturbation of idiotype-
anti-idiotype interactions. A recent review
by Roitt et al. (1981) illustrates the
complexity of idiotypic networks in con-
trol of antibody production and hence
the difficulty of predicting the effects of
cytotoxic chemotherapy in human disease.
The picture is further complicated by
specific and nonspecific immunosuppres-
sive effects of the tumour which are re-
moved during successful chemotherapy.
Impairment of reticuloendothelial func-
tion by cytotoxic chemotherapy, as pre-
viously demonstrated in rats (Sharbaugh
& Grogan, 1969) and man (Magarey &
Baum, 1970; Lokich et al., 1974), may also
impair clearance of normally occurring
or tumour-related CIC from the circula-
tion. Cytotoxic drugs could achieve this
by depletion of monocytes of marrow
origin which probably develop into tissue-
fixed macrophages, such as Kupffer cells,
responsible for clearing CIC for the cir-
culation (for review see Lancet, 1980).
There are unfortunately few malignan-
cies other than GTT and MT which are
chemosensitive and also have a satis-
factory biochemical tumour-marker
system. Analysis of the value of CIC
assays in the more common cancers
cannot, therefore, be readily assessed by
such stringent criteria. Given the small
amount of data published in conditions
in which relapses during chemotherapy
are common (such as carcinoma of the
ovary), it may be difficult to be certain
whether rises in CIC concentrations which
appear to predict relapse (Poulton et al.,
1978) are caused by recurrent tumour
or by the chemotherapy itself.
The various currently available assays
for CIC are based on recognition of the
alterations which occur to antibody when
it comes complexed, but may nevertheless
give different results in the same disease
state (Lambert et al., 1978). These methods
do not distinguish between CIC with
different antigen components such as
tumour products, normal-tissue antigens,
non-antigen-containing y-globulin aggre-
gates and specific antiglobulin complexes.
It therefore seems unlikely that any of
these assays will be much more specific
than those used in this study. This should
221222 R. H. J. BEGENT EY AL.
not be allowed to obscure the possibility
that some CIC may contain as yet un-
recognized tumour products which are
relatively tumour-specific. The value of
direct tumour products such as hCG and
AFP in monitoring the clinical course of
GTT and MT illustrated in this study
encourages characterization ofthe antigen
components of CIC in more common
human malignancies, in a search for other
tumour products which may have appli-
cation as tumour markers.
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